Financial News Feed

Today VTGN ranks # as SELL CANDIDATE.
Today VTGN ranks # as SELL CANDIDATE.

VTGN stock VistaGen Therapeutics Inc

VTGN stock
VistaGen Therapeutics Inc

Moving Average Convergence Divergence, or MACD, is a trend-following (lagging) momentum indicator that shows the relationship between two different moving averages. MACD is calculated when you subtrac...

Read more

Investors will be closely watching to see if the firm can move towards the $16.5 time high as the Bull Bear Power number stands at -0.072356544. Investors may be wondering what’s in store for the ne...

Read more

Vistagen Therapeutics Inc (NASDAQ:VTGN) has received an average rating of “Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst h...

Read more

Analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report $-0.30 EPS on February, 11.They anticipate $0.06 EPS change or 25.00 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS pre...

Read more

Investing in the stock market has traditionally offered bigger returns than other types of investments. Along with the opportunity for higher returns comes a higher amount of risk. Stocks can be expos...

Read more

Vistagen Therapeutics Inc (NASDAQ:VTGN) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One analy...

Read more

Doing standard fundamental stock analysis is fairly straightforward. These days, investors have easy access to large amounts of available data. The biggest problem for the average investor may be dedi...

Read more

Analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report $-0.30 EPS on February, 11.They anticipate $0.06 EPS change or 25.00 % from last quarter's...

Read more

Today it was reported that the CEO of VistaGen Therapeutics (VTGN), Shawn Singh, exercised options to buy 25,375 VTGN shares at $1.50 a ... The post The CEO of VistaGen Therapeutics is Exercising Opti...

Read more

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers...

Read more

Tracking some historical stock price data for VistaGen Therapeutics, Inc. (:VTGN), we note that performance has been positive over the last 52-week period. During that time, the stock has risen 39.34%...

Read more

(MENAFN - GlobeNewsWire - Nasdaq) itemprop="articleBody">SOUTH SAN FRANCISCO, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage bioph......

Read more

Analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report $-0.30 EPS on February, 11.They anticipate $0.06 EPS change or 25.00 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS pre...

Read more

Analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report $-0.30 EPS on February, 11.They anticipate $0.06 EPS change or 25.00 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS pre...

Read more

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure. On January 7, 2019, VistaGen Therapeutics, Inc. (the“Company”) began utilizing a n...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank